Trace Life Sciences and Macrocyclics Announce Project Collaboration

DALLAS, Aug. 16 Trace Life Sciences and Macrocyclics, Inc.have announced that the two companies will work together on customer projectsthat require labeled bifunctional chelates for radiopharmaceuticalapplications. Macrocyclics currently manufactures bifunctional chelatingagents that safely link radioisotopes to biological targeting molecules suchas antibodies which are valuable tools for imaging and therapy of diseasessuch as cancer. Trace Life Sciences is a leading producer of radioisotopes formedical imaging and therapy. In particular Trace is now providing GMP gradeisotopes such as Cu-64 which promises to have great utility for thefast-growing PET imaging market and Cu-67 which is a key isotope sought afterfor Radioimmunotherapies (RITs). The close proximity of the two companiesprovides the ideal environment for rapid production of labeled products whichcan benefit early-stage clinical development projects.

"We are delighted to have this agreement with our Texas neighbor to helpbring the benefits of both companies together - aside from offeringradioisotopes to industry and research, this partnership with the talentedteam at Macrocyclics gives us another dimension to now offer labeled ligandsand custom synthesis to the research market in one step. Researchers can nowfocus on their work and not on the often cumbersome and difficult labelingtask," said Darren Brown, CEO of Trace Life Sciences.

"The collaboration with Trace Life Sciences will expand the scope of ourofferings to the radiopharmaceutical community - we can now help customersinterested in accelerating advanced research and clinical development programsby providing labeled complexes for imaging and therapeutic applications," saidGarry Kiefer, Director of Operations, Macrocyclics.

This release was issued through eReleases(TM). For more information,visit http://www.ereleases.com.For more information, contact: Meagan Skarbek General Manager, Macrocyclics Tel: 972-250-2248 E-mail: [email protected] http://www.macrocyclics.com Tracey Lane Vice President, Trace Life Sciences Tel: 940-383-6100 E-mail: [email protected] http://www.tracelifesciences.com

SOURCE Macrocyclics, Inc.

Latest Press Release on General News

World IBS Day - April 19th: Raising Awareness for Everyone with IBS

Debunking myths about Irritable Bowel Syndrome TORONTO , April 18, 2024 /PRNewswire/ -- IBS is a chronic gastrointestinal disorder with symptoms like abdominal pain, bloating,...

Important step taken on the Canada Disability Benefit in Budget 2024, but funding falls short

More work must be done to lift Canadians with disabilities out of poverty TORONTO , April 17, 2024 /CNW/ - The federal government has taken an important step on the Canada Di...

Hydrinity Accelerated Skin Science Introduces MicroFusion Technology and Expands Facial Skincare Line with PRELUDE Facial Treatment Cleanser and HYDRI-C Vitamin C Moisturizer

The Next Generation Technology with the Power to Transform Skin MONROE, La. , April 15, 2024 /PRNewswire/ -- Hydrinity Accelerated Skin Science announced today the launch of t...

A 2017 Hyundai Elantra and 760,000 kilometres of life-saving blood donation deliveries

Mr. Tim German's 2017 Hyundai Elantra a.k.a. "Dark Angel," was bought new from Steele Hyundai Halifax and now has more than 760,000 kilometres on the odometer. With his Elantra, Mr....

Philips Respironics Reaches Agreement with US Government on a Consent Decree Creating a Clear Path Forward

April 10, 2024 Philips confirms that further to communicating the main terms of the Philips Respironics consent decree on January 29, 2024, Philips’ subsidiaries Philips Holding USA ...